A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Endeavor Biomedicines, Inc.
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
GE Healthcare